Sarepta Therapeutics, Inc. 8-K

What Happened
Sarepta Therapeutics announced on July 27, 2026 (filed 8-K) that its Board appointed Michael Severino, M.D., as Chief Executive Officer effective July 28, 2026; he also was appointed a Class I director to serve until the 2028 annual meeting. Current CEO Douglas Ingram will step down from the CEO role and the Board effective July 28, 2026, and will serve as a consultant to Sarepta under a Consulting Agreement through December 31, 2026 for $15,000 per month.

Key Details

• Employment Agreement dated July 24, 2026: Severino’s initial term is 3 years with automatic one-year renewals unless either party gives 60 days’ notice. Base salary: $1,180,000; target annual bonus: 110% of base salary. 2026 bonus: paid at 100% of target, prorated for time employed.
• Sign‑On Grant ≈ $35,000,000 (grant‑date value), composed of: ~$6M (prorated 2026 annual grant), ~$12M (2027 annual grant), ~$3M (new‑hire grant), and ~$14M Make‑Whole grant to compensate forfeited awards. Structure: ~1/3 restricted stock units (annual vesting over 4 years) and ~2/3 premium‑priced stock options (25% vest at 1 year, then monthly over 3 years). Severino is not expected to receive a separate 2027 annual grant because it’s included in the sign‑on package.
• Severance and change‑of‑control terms: For a qualifying termination outside the change‑of‑control period, Severino gets 18 months of base salary continuation, target bonus for year of termination, pro‑rata bonus, COBRA employer cost for up to 18 months, outplacement up to $20,000, full acceleration of the Make‑Whole Grant and 12 months’ accelerated vesting of the Sign‑On Grant (subject to release). If termination occurs during the change‑of‑control period, severance is enhanced to 24 months’ salary and 2× target bonus (lump sum), pro‑rata bonus paid in lump sum, and full acceleration of all time‑based equity awards.
• Other terms: perpetual confidentiality and IP assignment covenants; 12‑month post‑employment non‑compete and non‑solicit restrictions. No related‑person transactions disclosed in connection with his appointment.

Why It Matters
A new CEO with an extensive biopharma leadership background (prior CEO of Tessera Therapeutics; senior R&D roles at AbbVie and Amgen; MD from Johns Hopkins) can affect strategy and investor expectations for Sarepta’s pipeline and commercialization efforts. The large sign‑on package (~$35M) and robust severance/change‑of‑control protections are material compensation events investors should note because they affect potential dilution, executive incentives, and cash/expense considerations. The consulting arrangement for outgoing CEO Douglas Ingram provides short‑term continuity through year‑end. The filings (Employment and Consulting agreements and a press release) are attached as exhibits to the 8‑K.